Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person VEGFA-165 dimer binds VEGFA inhibitors

Class:Id	Reaction:9679477
_displayName	VEGFA-165 dimer binds VEGFA inhibitors
_doRelease	TRUE
_timestamp	2020-06-10 09:30:58
authored	[InstanceEdit:9679468] Jassal, Bijay, 2020-03-24
compartment	[Compartment:984] extracellular region
created	[InstanceEdit:9679468] Jassal, Bijay, 2020-03-24
edited	[InstanceEdit:9679468] Jassal, Bijay, 2020-03-24
input	[CandidateSet:9679456] VEGFA inhibitors [extracellular region] [Complex:4420158] VEGFA-165 dimer [extracellular region] [Homo sapiens]
isChimeric	FALSE
literatureReference	[LiteratureReference:9679491] Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors [LiteratureReference:9679484] Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations [LiteratureReference:9679489] Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study [LiteratureReference:9685108] VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer [LiteratureReference:9685080] Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration [LiteratureReference:9679454] Pegaptanib for neovascular age-related macular degeneration [LiteratureReference:9685063] Pegaptanib in the treatment of wet, age-related macular degeneration [LiteratureReference:9685089] Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration [LiteratureReference:9685068] Vascular endothelial growth factor is a critical stimulus for diabetic macular edema [LiteratureReference:9685083] First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors [LiteratureReference:9685091] The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
modified	[InstanceEdit:9685099] Jassal, Bijay, 2020-04-22 [InstanceEdit:9685409] Jassal, Bijay, 2020-04-23 [InstanceEdit:9687446] D'Eustachio, Peter, 2020-05-08 [InstanceEdit:9688550] Jassal, Bijay, 2020-05-14 [InstanceEdit:9688754] Jassal, Bijay, 2020-05-14 [InstanceEdit:9691218] Jassal, Bijay, 2020-06-10 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	VEGFA-165 dimer binds VEGFA inhibitors
output	[Complex:9679453] VEGFA-165 dimer:VEGFA inhibitors [extracellular region] [Homo sapiens]
releaseDate	2020-06-10
reviewed	[InstanceEdit:9688552] Shoichet, Brian, 2020-05-14
reviewStatus	[ReviewStatus:9821382] five stars
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:9679502] R-HSA-9679477.3
summation	[Summation:9685053] In normal development vascular endothelial growth factors (V...
(hasEvent)	[Pathway:4420097] VEGFA-VEGFR2 Pathway [Homo sapiens] [Pathway:9679191] Potential therapeutics for SARS [Homo sapiens]
(updatedInstance)	[_UpdateTracker:9776918] Update Tracker - [Reaction:9679477] VEGFA-165 dimer binds VEGFA inhibitors - v74:[add_removeInput]
[Change default viewing format]

No pathways have been reviewed or authored by VEGFA-165 dimer binds VEGFA inhibitors (9679477)